@article {NAKAGAWA6665, author = {NOBUHIKO NAKAGAWA and KATSUHITO TANAKA and FUMINORI SONOHARA and RAJU KANDIMALLA and YUKI SUNAGAWA and YOSHIKUNI INOKAWA and HIDEKI TAKAMI and MASAMICHI HAYASHI and SUGURU YAMADA and MITSURO KANDA and CHIE TANAKA and GORO NAKAYAMA and MASAHIKO KOIKE and YASUHIRO KODERA}, title = {Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue}, volume = {40}, number = {12}, pages = {6665--6676}, year = {2020}, doi = {10.21873/anticanres.14690}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: N6-Methyladenosine (m6A), the most abundant internal modification of RNA, plays a critical role in cancer development. However, the clinical implications of m6A in hepatocellular carcinoma (HCC) remain unclear. Materials and Methods: We analyzed 177 HCC and paired noncancerous liver tissues from patients who underwent hepatectomy according to global m6A quantification and expression of m6A demethylases fat mass and obesity-associated protein (FTO) and alpha-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKBH5). Results: The global m6A quantification revealed no significant difference between HCC and non-cancerous tissue. The expression of m6A demethylases FTO and ALKBH5, was significantly lower in HCC than in non-cancerous tissues (both p\<0.001). Furthermore, low ALKBH5 expression in non-cancerous tissues was significantly correlated with worse recurrence-free survival (median of 16.3 vs. 38.9 months, p=0.001). Conclusion: m6A in HCC and its demethylase in surrounding non-cancerous liver tissues might be involved in inherent mechanisms for HCC development and affect malignant potential after HCC resection.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/12/6665}, eprint = {https://ar.iiarjournals.org/content/40/12/6665.full.pdf}, journal = {Anticancer Research} }